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Few studies on the concomitant effects of beclomethasone dipropionate and asthma-related
factors on the growth of prepubertal asthmatic children have been published to date. In this
prospective long-term ‘real-life’ cohort study we recruited 82 prepubertal steroid-naı¨ve asth-
matic patients aged 3 þ years, excluding those with birth weight lower than 2500 g, malnutri-
tion, and other concurrent chronic diseases. Height/age and weight/age Z scores were
calculated every three months. Random effects multivariate longitudinal data analysis was
used to adjust height/age and weight/age Z scores with independent variables. Among the
studied patients, 63.4% were male, aged 4.7  1.5 years, 68.3% suffered from severe persistent
asthma and had normal values for height/age and weight/age Z scores at enrolment. They
were followed for 5.2 years (range 2.3e6.1) and used a mean daily beclomethasone dipropio-
nate dose of 351.8 mcg (range 137.3e1140.0). Height/age and weight/age Z scores were not
affected by either duration of treatment or doses of beclomethasone dipropionate up to
500 mcg, 750 mcg and higher than 750 mcg (p-values > 0.17). The multivariate analysis final
model showed that severe persistent asthma was associated to lower height for age Z score
(p Z 0.04), whereas hospitalizations because of acute asthma (before and during follow-up)
were associated (p Z 0.02) to lower weight for age Z score. Growth parameters were not
affected by the use of beclomethasone dipropionate.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
An ideal inhaled corticosteroid (ICS) should demonstrate
high pulmonary deposition and residence time, in addition
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previous generation (beclomethasone, triamcinolone and
flunisolide),2 which means fewer side effects.
The oral bioavailability of beclomethasone dipropionate
(BDP) is twice and four times higher than that of budeso-
nide and fluticasone, respectively.1 Therefore, it is relevant
to assess the long-term repercussions on growth of children
under treatment with the different inhaled corticosteroids
and in diverse settings.
Medium-term studies have addressed growth between 6
and 24 months of follow-up, while longer term studies have
assessed growth for over 24 months and up to adulthood.3
Given the inherent difficulties in carrying out long-term
longitudinal studies with children (including prepubertal
ones), the meta-analysis by Allen et al. has reported only 4
studies on the effects of BDP on growth over 3.8 years of
follow-up. These 4 studies had a relatively small sample
size (from 29 to 52) of subjects older than 7.5 years.4
In a review paper, Doull3 reported only five long-term
studies on the effects of ICS on growth. Only one investi-
gated the effects on height of up to 600 mcg/day of BDP in
26 prepubertal children, and reported no detrimental
effect.3,5 However, the study also included younger chil-
dren aged from 1.1 year, and, it is recommended2,6 that the
assessment of ICS effects on the growth of prepubertal
children should include only subjects over 3e4 years,
bearing in mind the hormonal and nutritional factors on
growth velocity in younger children.2,6 Moreover, it is worth
pointing out that children below this age should, in all
cases, be studied separately, and factors such as birth
weight and nutrition be taken into account.6 Likewise,
Pedersen suggested that more pediatric safety studies are
needed, particularly in young age groups and concerning
long-term inhaled corticosteroid therapy.2
Prospective long-term (over 24 months) studies assessing
simultaneously the effects of BDP on height and weight
standard deviation scores as well as asthma features in
prepubertal asthmatic children are scarce in the literature.
It is well known that because of its relatively lower cost,
BDP-CFC is still widely prescribed in developing countries,
and that BDP-HFA also has its share in the developed world.
Effects of ICS on growth patterns should be studied in
diverse settings with different environmental and living
conditions, as well as ethnical, genetic, and nutritional
aspects. Taking into account these issues, the present study
aimed at analyzing the effects of beclomethasone dipro-
pionate (BDP)-CFC and factors related to asthma on the
growth of prepubertal children.
Methods
Study setting
The ISAAC Phase Three study has shown that among Bra-
zilian prepubertal children aged 6e7 years, the prevalence
of wheezing in the previous 12 months and of severe
persistent asthma were 24.3% and 6.1%, respectively.7
To face this significant public health issue an asthma
management program e the ‘‘Wheezy Child Program’’ - was
implemented in Belo Horizonte, Brazil, within the munic-
ipal health system network and targeted at children andadolescents from underprivileged families. Two of the
program’s assumptions were that patients with mild
persistent asthma should be followed at primary health
care facilities and that moderate-persistent severe asthma
cases should only be assisted at one out of four outpatient
referral clinics (ORCs) by pediatric pulmonologists or
allergologists.Study design, participants, inclusion and exclusion
criteria
This ORC-based, prospective ‘real-life’ observational long-
term cohort study, carried out in the Campos Sales ORC
from January 2005 to December 2008, included prepubertal
steroid-naı¨ve children, with height and weight measure-
ments within the normal range of Z scores, suffering from
moderate to severe persistent asthma, aged 3 þ years, with
a Tanner sexual maturity rating equal to 1,8 who required
regular treatment with inhaled corticosteroids, and who
were followed up to the age of 9 (females) or 9.5 (males).
For instance, if a boy started BDP at the age of 8, the
observation period was interrupted at age 9.5, even if that
patient continued on BDP for uncontrolled asthma.
The lower and upper age limits for both sexes were pre-
defined according to recommendations set by Price et al.6
to avoid influence of sex corticosteroids.2 Save those who
met the exclusion criteria, all the eligible prepubertal
patients from the ORC were admitted into the study.
BDP-CFC was (and still is) the ICS standardized by the
Belo Horizonte Municipal Health Authority (BHMHA), and
was dispensed free of charge to all study participants. It
was delivered through a large volume (650 mL) pear-shaped
plastic valved spacer (Flumax, Flumax Medical Equip-
ments, Belo Horizonte, Brazil), also provided free of
charge. BDP-CFC and spacers were only dispensed at the
pharmacy clinic, and the participants were deemed unable
to obtain them elsewhere being from low-income families.
Due to budgetary constraints, add-on anti-asthmatic drugs
were not provided by the BHMHA. The quality of inhalation
technique, checked by trained nurses, was verified at every
follow-up visit, and mouth-washing after inhalation was
routinely recommended.
Exclusion criteria were pre-defined as follows: prepu-
bertal children with birth weight below 2500 g, current
malnutrition (weight less than 2 Z score), chronic diseases
and use of systemic glucocorticoids for more than two
weeks per year to treat asthma exacerbations.
We recorded growth measurement values (see next
topic) at each three month follow-up visit, as well as data
on sex, age, monthly family income, mother’s schooling
level, previous hospitalizations because of acute asthma,
emergency room visits, duration of asthma before BDP
treatment, BDP dose, and asthma severity.
In a specific form the pharmacist recorded data per-
taining to number of canisters dispensed, therapeutic
regimen, dates when empty canisters were returned and
new ones dispensed, upon which a new inhaler was
provided. When the child was not present on the predicted
date for canister exchange, he or she was classified as BDP
non-user until contacted by the health team and resumed
use of ICS. The possibility of a patient acquiring medication




Mean 4.7  1.5
Median 4.3
Range 3.0e8.1
Family monthly income e US$
Mean 257.00  105.00
Mother schooling level e yr 5.6  3.1
Previous hospitalizations due to acute asthma e no.
Median 4.0
Range 3.0e30.0
Emergency room visits e no.
Median 2
Range 1e8
Duration of asthma e months 25.9  23.8
Moderate/severe persistent asthma 26/56
Height/age Z score
Mean 0.11  1.21
Range 2.74e2.94
Weight/age Z score
Mean 0.04  1.21
Range 2.42e5.00
Beclomethasone, asthma and growth 953outside the public health system was virtually zero, and all
patients assisted by the asthma management program were
forbidden to obtain BDP in any other pharmacy of the public
health system and deemed unable to afford BDP or any
other ICS. Dose in micrograms/day was calculated by
number of micrograms in each canister, number of days
elapsed between dispensation and canister return. BDP use
was classified in four categories, as follows: ‘‘none’’ (i.e.,
non-user) when the patient discontinued the treatment
temporarily; up to 500 mcg; 500 mcg to 750 mcg and, more
than 750 mcg/day, i.e., 4 or more puffs/day.
Height and weight measurements
To allow comparisons with other studies on this subject,
height and weight values obtained in the study population
are matched with reference standards for height for age Z
scores (HAZ) (in centimeters) and weight for age Z scores
(WAZ) (in kilograms) growth charts reported by the US
National Center for Health Statistics/Centers for Disease
Control (NCHS-CDC, 2000).9 These standards have been
widely used in Brazil and abroad since their publication,
before and during the study period. To ensure precision and
accuracy, all height and weight measurements were per-
formed every three months throughout the study by the
same pediatric pulmonologist, using the same apparatus.
All subjects had a Harpenden stadiometer measurement
(ranging from 60.0 cm to 210.0 cm, with 2 m length, wall
mounted, with precision to 0.1 cm), checked every day and
calibrated weekly, of standing height barefoot positioned in
such a way that the head, shoulders, buttocks and calves
lightly touched the wall. Height duplicate measurements
were recorded in centimeters and the arithmetic mean of
the two measurements used for analysis, with a maximum
of 0.1 cm allowed between the two measurements. Body
weight was measured using a conventional scale (Filizola,
Filizola Ltd., Sa˜o Paulo, Brazil), with capacity for 100 kg,
periodically calibrated. The subjects were weighted bare-
foot and wearing light clothing.
Asthma definition, severity and treatment
GINA recommendations were used for the diagnosis, clas-
sification of severity, and treatment regimen (10). BDP dose
was titrated according to asthma severity.10
Statistics
The primary endpoints were the height for age (HAZ) and
weight for age (WAZ) Z scores and growth velocity (cm/
year). The effects of the previously mentioned co-variables
on HAZ and WAZ scores were analyzed through the random
effects model for longitudinal data.11 All p-values are two-
tailed, and the significance level was p < 0.05.
Ethics
The study protocol and documentation form, as well as the
informed consent form were approved by the Ethics
Committee of the Federal University of Minas Gerais.Results
Descriptive characteristics of the participants
We recruited and followed 82 registered prepubertal chil-
dren, whose descriptive characteristics are shown in Table 1.
At admission, the majority (63.4%) of patients were
male, came from low-income families and had mothers
with five of the eight years of basic schooling in Brazil
completed. Most (68.3%) suffered from severe persistent
asthma that had led to frequent hospitalizations. They
were, however, well-nourished and with mean and median
HAZ and WAZ scores within the normal range.
The mean duration of the follow-up was 5.2 years
(range, 2.3e6.1) and the mean cumulative prescribed dose
of BDP at the end of the follow-up was 569.9 mg (range,
90 mge2.394,8 mg) for the whole cohort. As the mean
duration of BDP treatment was 4.5 years (range, 1.9e5.8),
the mean average daily BDP dose was 351.8 mcg (range,
137.3e1140.0 mcg).
Primary endpoints
Fig. 1 shows the HAZ and WAZ scores curves according to
the BDP pharmacy recordings data compared with NCHS
2000 growth charts.
Overall, growth in height and weight had a similar
pattern. For BDP non-users (‘‘none’’/temporarily non-user
category, as stated previously) and users for which up to
500 mcg/day was prescribed in a given period, the HAZ and
WAZ scores did not show any deviation throughout the
study. Similar results were obtained for patients in the two
higher dosage categories (500e750 mcg/day and more than
Figure 1 Height for age (A) and weight for age (B) Z scores
curves of the studied population compared with NCHS 2000
growth charts.
954 P.A.M. Camargos, L.M.L.B.F. Lasmar750 mcg/day) after the age of 5. There was an initial slight
(less than 1 standard deviation) deceleration, with poste-
rior catch-up in both HAZ and WAZ scores for subjects aged
3e4 years taking doses over 500 mcg/day of BDP. There
were no statistical differences in the univariate analysis
when each of the four categories of BDP dosage was
analyzed against HAZ and WAZ scores (all p-values > 0.17).
Table 2 displays the multivariate analysis for longitudinal
data final model results: lower HAZ score was related to
severe persistent asthma (p Z 0.04), i.e., prepubertal
children suffering from severe asthma had Z scores 0.47
standard deviations lower than that suffering from
moderate asthma while the occurrence of hospitalizations
(before and during the follow-up) was associated (pZ 0.02)
with lower WAZ score, i.e., hospitalized subjects had Z
scores 0.10 standard deviations lower than non-hospitalizedTable 2 Relationship between factors related to asthma
and growth of the studied population compared with NCHS
2000 growth charts.
Outcome/co-variable b SD p-value
Effect on HAZ score
Severe asthma 0.467 0.47 0.040
Effect on WAZ score
Hospitalizations for acute
asthma before and during
the follow-up
0.233 0.101 0.028
b Z regression coefficient; SD Z standard deviation;
HAZ Z height for age Z score; WAZ Z weight for age Z score.ones. However, this is not clinically relevant because the
values are within the normal range (from 2 to 2) of the Z
score.Discussion
Normal growth occurs rapidly during the first 2e3 years of
life and is predominantly determined by birth weight and
nutritional status; followed by childhood growth up until
puberty, when it is dependent on the secretion of growth
hormone. Thus, younger, prepubertal children, seem to be
more sensitive to the growth-suppressive effects of ICS than
infants and pubertal schoolchildren.2,3 According to Price
et al. for children over the age of 3, successive height
measurements are highly correlated because children
generally remain in the same height percentile until the
onset of puberty.6 Moreover, height at a particular age
correlates well with final height, because there is a high
probability of an individual remaining within the same
height percentile after a period of time.6 Therefore, we
examined not only the potential effects of BDP-CFC, but
also the factors related to asthma itself in a long-term
study, with a cohort comprised exclusively of moderate to
severe prepubertal asthmatic children using only BDP-CFC.
Despite the wide use of BDP-CFC since the 1970s and the
availability of extrafine and non-extrafine HFA preparations
in the 2000s, there have been few studies with the same
design as the present.
Overall, asthma seemed not to affect the expected adult
height in the majority of patients and the most perceived
growth impairment is related to pubertal delay.3 Adult
height, however, could possibly be decreased in severe
asthmatics, but this should not be superior to 1.2 cm3
Among the asthma co-variables analyzed in the present
study, severe persistent asthma was associated to lower
height for age Z score (pZ 0.04), whereas hospitalizations
because of acute asthma (before and during follow-up)
were associated (pZ 0.02) to lower weight for age Z score.
Previous short-term studies (less than six months of
follow-up) with less than 20 schoolchildren, showed that
individual intake of 400 or 800 mcg of BDP led to decreased
short-term growth, assessed by knemometry.3,12,13 In the
present study, there was a similar but not statistically
significant tendency in growth retardation for children aged
3e4 years receiving doses higher than 500 mcg of BDP,
measured by stadiometry, even though the two methods
are not comparable.
Four medium-term studies, carried out with school-
children aged 6e9 years, found that BDP doses higher than
300 mcg were related to some degree of growth suppres-
sion. However, the follow-up duration was shorter than 24
months and thus could not verify the occurrence of catch-
up growth in subsequent years.3,14e17 A shown in Fig. 1, the
relative deceleration found in some of our patients gave
way to a catch-up by the end of follow-up for both HAZ and
WAZ scores.
Among the five long-term studies cited by Doull,3 two
analyzed the effects of budesonide,18,19 two others assessed
the final adult height of adolescents or young adults20,21 and
only one examined 26 children under a dosage of BDP up to
600 mcg/day before puberty and 400 mcg/day during
Beclomethasone, asthma and growth 955puberty.5 However, despite subjects reaching the predicted
adult height and the author’s conclusion that asthma had no
direct influence in height, the mean age of entry for this last
study was 7.5 years (range, 1.9e12.1 years), which hinders
comparisons with our study.
Allen et al. carried out a meta-analysis of twelve other
studies on the effects of BDP on height. All of them verified
this effect in children older than 7 years and for a period
ranging from 0.9 to 5.8 years.4 Even though their pop-
ulations are very different from ours, there was no associ-
ation between BDP and decreased stature. Conversely, in
another meta-analysis, Sharek & Bergman concluded that
1) moderate doses of BDP in children with mild to moderate
asthma leads to a decrease in linear growth of 1.51 cm/
year; and 2) the effects of inhaled steroids when taken for
more than 54 weeks e or in the final adult height e remain
unknown.22
There are two other published studies not included in
the above-mentioned meta-analyses. The first one
recruited 201 prepubertal children, aged 1e11 years (mean
4.4 years) receiving between 100 and 2.500 mcg of BDP or
budesonide for up to 5 years.23 Disregarding the difference
in the study population (ours included children aged 3 to
9e9.5 years), results were different and the authors
concluded that a longer therapy was associated with more
growth retardation. Our study, however, demonstrated
a catch-up after the age of 5 years for those children who,
between ages 3 and 5, presented a slight growth retarda-
tion when taking 500e750 mcg of BDP
In the second study, children aged 1e15 years who
received over 400 mcg of a non-specified ICS had lower
height and weight than average, and children with asthma
showed no growth impairment. However, as in our cohort,
where monthly family income was correlated with
a decrement in HAZ score (p Z 0.036) in the univariate
analysis, the authors found that social deprivation had an
adverse effect on height and weight, irrespective of any
disease process.24
This brief literature review shows that effects of ICS in
growth remain polemical. Unfortunately, we found no study
with a design similar to ours, but the results point to the
absence of any impairing and clinically relevant effect on
growth, be it caused by asthma or by BDP use in prepu-
bertal asthmatic schoolchildren. Since height assessments
at a particular age correlates well with final height,6 our
results concur with those obtained in the most compre-
hensive cohort carried out on this subject in children.19 In
that landmark study, no statistical significance was
observed in the final adult height between children treated
with a mean daily dose of budesonide (BUD) of 412 mcg for
9.2 years (þ0.3 cm), non-BUD treated asthmatic controls
(0.2 cm), and healthy siblings controls (þ0.9 cm).19
In view of the still existing controversial results com-
mented above, until further studies clarify the real effects
of ICS on growth, it is advisable that during the treatment
of every prepubertal asthmatic child, clinicians should
prescribe the lowest possible dose of BDP or any other ICS
to achieve asthma control. According to our results, if
a patient requires more than 500 mcg, and especially, more
than 750 mcg of BDP-CFC (the same dose of BDP-HFA non-
extrafine preparations) or 250e372 mcg of BDP-extrafine
preparation or the equivalent dose of other ICS, theclinician should also: 1) regularly monitor height and weight
(preferably every 3e6 months); 2) reassess the adherence
rate; and 3) judiciously prescribe add-on anti-asthmatic
drugs in order to avoid higher BDP/ICS intake and its
potential adverse effects on growth.Acknowledgements
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